Volume 9, Issue 2 (Journal of Clinical and Basic Research (JCBR) 2025)
jcbr 2025, 9(2): 21-27 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Jafari-Sales A, Meskini-Marandi S, Khakpour-Ziaei S, Valipour S, Pashazadeh M. The hidden yet threatening link between hepatitis B virus and hepatocellular carcinoma: A Narrative Review. jcbr 2025; 9 (2) :21-27
URL: http://jcbr.goums.ac.ir/article-1-514-en.html
URL: http://jcbr.goums.ac.ir/article-1-514-en.html
Abolfazl Jafari-Sales1 
, Safa Meskini-Marandi2 , Shabnam Khakpour-Ziaei2 , Sadra Valipour2 , Mehrdad Pashazadeh *3
, Safa Meskini-Marandi2 , Shabnam Khakpour-Ziaei2 , Sadra Valipour2 , Mehrdad Pashazadeh *3
1- Department of Microbiology, Kaz.C., Islamic Azad University, Kazerun, Iran; Infectious Diseases Research Center, TaMS.C., Islamic Azad University of Medical Sciences, Tabriz, Iran
2- Infectious Diseases Research Center, TaMS.C., Islamic Azad University of Medical Sciences, Tabriz, Iran; Department of Cellular and Molecular Biology, Ta.C., Islamic Azad University, Tabriz, Iran
3- Infectious Diseases Research Center, TaMS.C., Islamic Azad University of Medical Sciences, Tabriz, Iran; Department of Medical Laboratory Sciences and Microbiology, TaMS.C., Islamic Azad University, of Medical Sciences, Tabriz, Iran ,mehrdadpashazadeh85@gmail.com
2- Infectious Diseases Research Center, TaMS.C., Islamic Azad University of Medical Sciences, Tabriz, Iran; Department of Cellular and Molecular Biology, Ta.C., Islamic Azad University, Tabriz, Iran
3- Infectious Diseases Research Center, TaMS.C., Islamic Azad University of Medical Sciences, Tabriz, Iran; Department of Medical Laboratory Sciences and Microbiology, TaMS.C., Islamic Azad University, of Medical Sciences, Tabriz, Iran ,
Abstract: (319 Views)
Background: Hepatocellular carcinoma (HCC) is a highly aggressive liver cancer (LC), primarily driven by chronic hepatitis B virus (HBV) infection. Persistent HBV infection causes liver inflammation, dysfunction, and ultimately HCC through mechanisms like viral integration, oncogenic protein expression, and immune disruption. This study explores HBV-related HCC mechanisms and evaluates preventive/therapeutic approaches to reduce the global HCC burden.
Methods: To conduct this comprehensive review, we systematically searched the databases of PubMed, Scopus, Web of Science, and Google Scholar for relevant literature. The search included studies published without a time restriction up to 2025, covering clinical studies, review articles, systematic reviews, and meta-analyses. The following keywords were used to identify pertinent publications: "HBV", "HCC", "Pathogenesis", "Immune response", "LC", "Diagnosis ", "Prevention", and "Treatment".
Results: HBV contributes to HCC through multiple mechanisms, including viral genome integration into the host, oncogenic viral protein expression, genetic mutations, induction of cellular proliferation, inhibition of apoptosis, immune system disruption, and alterations in cellular signaling pathways. Antiviral therapies targeting HBV have shown promise in reducing HCC risk by suppressing viral replication and mitigating liver damage. Early intervention in CHB patients significantly decreases HCC incidence, highlighting the importance of timely diagnosis and treatment.
Conclusion: The strong link between HBV and HCC underscores the need for effective antiviral strategies to prevent and manage HCC. Understanding the molecular mechanisms of HBV-induced hepatocarcinogenesis is crucial for developing targeted therapies. Preventive measures, including vaccination and early antiviral treatment, are essential in reducing the global HCC burden.
Methods: To conduct this comprehensive review, we systematically searched the databases of PubMed, Scopus, Web of Science, and Google Scholar for relevant literature. The search included studies published without a time restriction up to 2025, covering clinical studies, review articles, systematic reviews, and meta-analyses. The following keywords were used to identify pertinent publications: "HBV", "HCC", "Pathogenesis", "Immune response", "LC", "Diagnosis ", "Prevention", and "Treatment".
Results: HBV contributes to HCC through multiple mechanisms, including viral genome integration into the host, oncogenic viral protein expression, genetic mutations, induction of cellular proliferation, inhibition of apoptosis, immune system disruption, and alterations in cellular signaling pathways. Antiviral therapies targeting HBV have shown promise in reducing HCC risk by suppressing viral replication and mitigating liver damage. Early intervention in CHB patients significantly decreases HCC incidence, highlighting the importance of timely diagnosis and treatment.
Conclusion: The strong link between HBV and HCC underscores the need for effective antiviral strategies to prevent and manage HCC. Understanding the molecular mechanisms of HBV-induced hepatocarcinogenesis is crucial for developing targeted therapies. Preventive measures, including vaccination and early antiviral treatment, are essential in reducing the global HCC burden.
Article Type: Review |
Subject:
Microbiology
References
1. Wang J, Qiu K, Zhou S, Gan Y, Jiang K, Wang D, et al. Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis. Ann Med. 2025;57(1):2455539. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Rayapati D, McGlynn KA, Groopman JD, Kim AK. Environmental exposures and the risk of hepatocellular carcinoma. Hepatol Commun. 2025;9(2):e0627. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Samanta T, Park JH, Kaipparettu BA. Biosocial Determinants of Health Among Patients with Chronic Liver Disease and Liver Cancer. Cancers. 2025;17(5):844. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Mazzola S, Vittorietti M, Fruscione S, De Bella DD, Savatteri A, Belluzzo M, et al. Factors Associated with Primary Liver Cancer Survival in a Southern Italian Setting in a Changing Epidemiological Scenario. Cancers. 2024;16(11):2046. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Huang J, Lok V, Ngai CH, Chu C, Patel HK, Thoguluva Chandraseka V, et al. Disease burden, risk factors, and recent trends of liver cancer: a global country-level analysis. Liver Cancer. 2021;10(4):330-45. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Israr MA. A Case Report of a Rapid Development of Hepatocellular Carcinoma (HCC) Within Six Months of Hepatitis C Cure in an Individual With Risk Factors. Cureus. 2025;17(2):e79571. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Lu W, Zheng F, Li Z, Zhou R, Deng L, Xiao W, et al. Association between environmental and socioeconomic risk factors and hepatocellular carcinoma: a meta-analysis. Front Public Health. 2022;10:741490. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Jiang L, Meng Q, Liu L, Li W. A Comprehensive Review on Molecular Mechanisms, Treatments, and Brief Role of Natural Products in Hepatocellular Cancer. Nat Prod Commun. 2024;19(9):1934578X241284873. [View at Publisher] [DOI] [Google Scholar]
9. Varghese N, Majeed A, Nyalakonda S, Boortalary T, Halegoua-DeMarzio D, Hann H-W. Review of related factors for persistent risk of hepatitis B virus-associated hepatocellular carcinoma. Cancers. 2024;16(4):777. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Choi W-M, Yip TC-F, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, et al. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients. Hepatology. 2024;80(2):428-39. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Allweiss L, Dandri M. The role of cccDNA in HBV maintenance. Viruses. 2017;9(6):156. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Polpichai N, Saowapa S, Danpanichkul P, Chan S-Y, Sierra L, Blagoie J, et al. Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma. J Clin Med. 2024;13(22):6770. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Rizzo GEM, Cabibbo G, Craxi A. Hepatitis B virus-associated hepatocellular carcinoma. Viruses. 2022;14(5):986. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Ringelhan M, O'Connor T, Protzer U, Heikenwalder M. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol. 2015;235(2):355-67. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepato. 2015;7(12):1708. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Ugbaja SC, Mokoena AT, Mushebenge AG-A, Kumalo HM, Ngcobo M, Gqaleni N. Evaluation of the Potency of Repurposed Antiretrovirals in HBV Therapy: A Narrative Investigation of the Traditional Medicine Alternatives. Int J Mol Sci. 2025;26(4):1523. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Gómez-Moreno A, Ploss A. Mechanisms of hepatitis B virus cccDNA and minichromosome formation and HBV gene transcription. Viruses. 2024;16(4):609. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Jafari-Sales A, Khakpour-Ziaei S, Meskini-Marandi S, Pashazadeh M. Impact of hepatitis B and C virus on chronic spontaneous urticaria; potential pathogenic triggers and aggravating factors. J Curr Biomed Rep. 2025. [View at Publisher] [DOI] [Google Scholar]
19. Mirzaei G, Shamsasenjan K, Jafari B, Bagherizadeh Y, Sadafzadeh A, Bannazadeh-Baghi H, et al. Prevalence of HBV and HCV infection in beta-thalassemia major patients of Tabriz city, Iran. New Microbes New Infect. 2021;43:100912. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. De Pauli S, Grando M, Miotti G, Zeppieri M. Hepatitis B virus reactivation in patients treated with monoclonal antibodies. World J Virol. 2024;13(1):88487. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. Bmj. 2020:370:m2200. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Ringlander J, Rydell GE, Kann M. From the Cytoplasm into the Nucleus-Hepatitis B Virus Travel and Genome Repair. Microorganisms. 2025;13(1):157. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. Mlewa M, Henerico S, Nyawale HA, Mangowi I, Shangali AR, Manisha AM, et al. The pattern change of hepatitis B virus genetic diversity in Northwestern Tanzania. Sci Rep. 2025;15(1):8021. [View at Publisher] [DOI] [PMID] [Google Scholar]
24. Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2:163-86. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010;52(4):594-604. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Boonstra A, Sari G. HBV cccDNA: The Molecular Reservoir of Hepatitis B Persistence and Challenges to Achieve Viral Eradication. Biomolecules. 2025;15(1):62. [View at Publisher] [DOI] [PMID] [Google Scholar]
27. Sneller L, Lin C, Price A, Kottilil S, Chua JV. RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects. Microorganisms. 2024;12(3):599. [View at Publisher] [DOI] [PMID] [Google Scholar]
28. Wei L, Ploss A. Mechanism of hepatitis B virus cccDNA formation. Viruses. 2021;13(8):1463. [View at Publisher] [DOI] [PMID] [Google Scholar]
29. Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses. 2017;9(4):75. [View at Publisher] [DOI] [PMID] [Google Scholar]
30. Geng M, Xin X, Bi L-Q, Zhou L-T, Liu X-H. Molecular mechanism of hepatitis B virus X protein function in hepatocarcinogenesis. World J Gastroenterol. 2015;21(38):10732-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
31. Rawat S, Bouchard MJ. The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival. J Virol. 2015;89(2):999-1012. [View at Publisher] [DOI] [PMID] [Google Scholar]
32. Sukowati CH, Jayanti S, Turyadi T, Muljono DH, Tiribelli C. Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: where we are now. World J Gastrointest Oncol .2024;16(4):1097-1103. [View at Publisher] [DOI] [PMID] [Google Scholar]
33. Castro GM, Sosa MJ, Sicilia PE, Riberi MI, Moreno C, Cattaneo R, et al. Acute and chronic HBV infection in central Argentina: High frequency of sub-genotype F1b, low detection of clinically relevant mutations and first evidence of HDV. Front Med. 2023;9:1057194. [View at Publisher] [DOI] [PMID] [Google Scholar]
34. Chen J, Li L, Yin Q, Shen T. A review of epidemiology and clinical relevance of Hepatitis B virus genotypes and subgenotypes. Clin Res Hepatol Gastroenterol. 2023;47(7):102180. [View at Publisher] [DOI] [PMID] [Google Scholar]
35. Sato K, Inoue J, Akahane T, Kobayashi T, Ninomiya M, Sano A, et al. Comparison of hepatitis B virus genotype B and C patients in Japan in terms of family history and maternal age at birth. Hepatol Res. 2025;55(5):773-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
36. Assefa A, Getie M, Getie B, Yazie TS, Enkobahry A. Molecular epidemiology of hepatitis B virus (HBV) in Ethiopia: a review article. Infect Genet Evol. 2024:122:105618. [View at Publisher] [DOI] [PMID] [Google Scholar]
37. Lin C-L, Kao J-H. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol. 2017;31(3):249-55. [View at Publisher] [DOI] [PMID] [Google Scholar]
38. Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol.
2010;52(3):441-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
39. Van Damme E, Vanhove J, Severyn B, Verschueren L, Pauwels F. The hepatitis B virus interactome: a comprehensive overview. Front Microbiol.
2021;12:724877. [View at Publisher] [DOI] [PMID] [Google Scholar]
40. Ren EC, Zhuo NZ, Goh ZY, Bonne I, Malleret B, Ko HL. cccDNA-Targeted Drug Screen Reveals a Class of Antihistamines as Suppressors of HBV Genome Levels. Biomolecules. 2023;13(10):1438. [View at Publisher] [DOI] [PMID] [Google Scholar]
41. Herrscher C, Roingeard P, Blanchard E. Hepatitis B virus entry into cells. Cells. 2020;9(6):1486. [View at Publisher] [DOI] [PMID] [Google Scholar]
42. Diogo Dias J, Sarica N, Neuveut C. Early steps of hepatitis B life cycle: from capsid nuclear import to cccDNA formation. Viruses. 2021;13(5):757. [View at Publisher] [DOI] [PMID] [Google Scholar]
43. Osseman Q, Gallucci L, Au S, Cazenave C, Berdance E, Blondot M-L, et al. The chaperone dynein LL1 mediates cytoplasmic transport of empty and mature hepatitis B virus capsids. J Hepatol. 2018;68(3):441-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
44. Prange R. Hepatitis B virus movement through the hepatocyte: An update. Biol Cell. 2022;114(12):325-48. [View at Publisher] [DOI] [PMID] [Google Scholar]
45. Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020;182:104925. [View at Publisher] [DOI] [PMID] [Google Scholar]
46. Kaur SP, Talat A, Karimi-Sari H, Grees A, Chen HW, Lau DT, et al. Hepatocellular carcinoma in hepatitis B virus-infected patients and the role of hepatitis B surface antigen (HBsAg). J Clin Med. 2022;11(4):1126. [View at Publisher] [DOI] [PMID] [Google Scholar]
47. D'souza S, Lau KC, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol.
2020;26(38):5759-83. [View at Publisher] [DOI] [PMID] [Google Scholar]
48. Arslan F, Franci G, Maria Nastri B, Pagliano P. Hepatitis B virus-induced hepatocarcinogenesis: A virological and oncological perspective. J Viral Hepat. 2021;28(8):1104-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
49. Elpek GO. Molecular pathways in viral hepatitis-associated liver carcinogenesis: An update. World J Clin Cases. 2021;9(19):4890-917. [View at Publisher] [DOI] [PMID] [Google Scholar]
50. Jiang Y, Han Q, Zhao H, Zhang J. The mechanisms of HBV-induced hepatocellular carcinoma. J Hepatocell Carcinoma. 2021:8:435-50. [View at Publisher] [DOI] [PMID] [Google Scholar]
51. Lin W-L, Hung J-H, Huang W. Association of the hepatitis B virus large surface protein with viral infectivity and endoplasmic reticulum stress-mediated liver carcinogenesis. Cells. 2020;9(9):2052. [View at Publisher] [DOI] [PMID] [Google Scholar]
52. Lin Y-T, Jeng L-B, Chan W-L, Su I-J, Teng C-F. Hepatitis B virus Pre-S gene deletions and Pre-S deleted proteins: clinical and molecular implications in hepatocellular carcinoma. Viruses. 2021;13(5):862. [View at Publisher] [DOI] [PMID] [Google Scholar]
53. Li Y, Xia Y, Cheng X, Kleiner DE, Hewitt SM, Sproch J, et al. Hepatitis B surface antigen activates unfolded protein response in forming ground glass hepatocytes of chronic hepatitis B. Viruses. 2019;11(4):386. [View at Publisher] [DOI] [PMID] [Google Scholar]
54. Zhang T-Y, Chen H-Y, Cao J-L, Xiong H-L, Mo X-B, Li T-L, et al. Structural and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction. Nat Commun. 2019;10(1):3192. [View at Publisher] [DOI] [PMID] [Google Scholar]
55. Yao J, Guo J, Xie Y. Hepatitis B virus induced cirrhosis and hepatocarcinoma: pathogenesis and therapeutics. Explor Dig Dis. 2025;4:100565. [View at Publisher] [DOI] [Google Scholar]
56. Kim S, Park J, Han J, Jang KL. Hepatitis B Virus X Protein Induces Reactive Oxygen Species Generation via Activation of p53 in Human Hepatoma Cells. Biomolecules. 2024;14(10):1201. [View at Publisher] [DOI] [PMID] [Google Scholar]
57. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589-604. [View at Publisher] [DOI] [PMID] [Google Scholar]
58. Xu Y, Xia C, Li H, Cao M, Yang F, Li Q, et al. Survey of hepatitis B virus infection for liver cancer screening in China: A population-based, cross-sectional study. Chin Med J. 2024;137(12):1414-20. [View at Publisher] [DOI] [PMID] [Google Scholar]
59. Zelber-Sagi S, Noureddin M, Shibolet O. Lifestyle and hepatocellular carcinoma what is the evidence and prevention recommendations. Cancers. 2021;14(1):103. [View at Publisher] [DOI] [PMID] [Google Scholar]
60. Mak L-Y, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. 2018;38(38):262-79. [View at Publisher] [DOI] [PMID] [Google Scholar]
61. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol. 2012;4(3):74-80. [View at Publisher] [DOI] [PMID] [Google Scholar]
62. Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, et al. Risk factors and prevention of viral hepatitis-related hepatocellular carcinoma. Front Oncol.
2021;11:686962. [View at Publisher] [DOI] [PMID] [Google Scholar]
63. Addissouky TA, Sayed IETE, Ali MM, Wang Y, Baz AE, Khalil AA, et al. Latest advances in hepatocellular carcinoma management and prevention through advanced technologies. Egypt Liver J. 2024;14(1):2. [View at Publisher] [DOI] [Google Scholar]
64. Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccines. J Infect Dis. 2021;224(Supplement_4):S343-S51. [View at Publisher] [DOI] [PMID] [Google Scholar]
65. Morgan HJ, Nold MF, Kattan GS, Vlasenko D, Malhotra A, Boyd JH, et al. Hepatitis B vaccination of preterm infants and risk of bronchopulmonary dysplasia: a cohort study, Australia. Bull World Health Organ. 2025;103(3):187-93. [View at Publisher] [DOI] [PMID] [Google Scholar]
66. Kim SK, Fujii T, Kim SR, Nakai A, Lim Y-S, Hagiwara S, et al. Hepatitis B virus treatment and hepatocellular carcinoma: controversies and approaches to consensus. Liver Cancer. 2022;11(6):497-510. [View at Publisher] [DOI] [PMID] [Google Scholar]
67. Chien R-N, Liaw Y-F. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022;14(2):434. [View at Publisher] [DOI] [PMID] [Google Scholar]
68. Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives. World J Gastroenterol.
2021;27(26):4018-44. [View at Publisher] [DOI] [PMID] [Google Scholar]
69. Mon H-C, Lee P-C, Hung Y-P, Hung Y-W, Wu C-J, Lee C-J, et al. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. J Hepatol. 2025;82(1):51-61. [View at Publisher] [DOI] [PMID] [Google Scholar]
70. Cao W-H, Zhang Y-Q, Li X-X, Zhang Z-Y, Li M-H. Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients. World J Hepatol. 2024;16(10):1158-68. [View at Publisher] [DOI] [PMID] [Google Scholar]
71. Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, et al. The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity. Mol Ther. 2021;29(5):1794-807. [View at Publisher] [DOI] [PMID] [Google Scholar]
72. Tan AT, Hang SK, Tan N, Krishnamoorthy TL, Chow WC, Wong RW, et al. A rapid method to assess the in vivo multi-functionality of adoptively transferred engineered TCR T cells. Immunother Adv. 2024;4(1):ltae007. [View at Publisher] [DOI] [PMID] [Google Scholar]
73. Healy K, Pavesi A, Parrot T, Sobkowiak MJ, Reinsbach SE, Davanian H, et al. Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions. JHEP Rep. 2021;3(4):100318. [View at Publisher] [DOI] [PMID] [Google Scholar]
74. Huang D, Ke L, Cui H, Li S. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2023;23(1):474. [View at Publisher] [DOI] [PMID] [Google Scholar]
75. Qin A, Ho M-C, Tsai C-Y, Liu C-J, Chen P-J. Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial. Hepatol Int. 2025;19(3):547-59. [View at Publisher] [DOI] [PMID] [Google Scholar]
76. Deng LX, Mehta N. Does hepatocellular carcinoma surveillance increase survival in at-risk populations? Patient selection, biomarkers, and barriers. Dig Dis Sci. 2020;65(12):3456-62. [View at Publisher] [DOI] [PMID] [Google Scholar]
77. Hu Y, Zhang Y, Jiang W. Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments .Clin Exp Med.
2025;25(1):57. [View at Publisher] [DOI] [PMID] [Google Scholar]
78. Woo ASJ, Kwok R, Ahmed T. Alpha-interferon treatment in hepatitis B. Ann Transl Med. 2017;5(7):159. [View at Publisher] [DOI] [PMID] [Google Scholar]
79. Koumbi L. Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol. 2015;7(8):1030-40. [View at Publisher] [DOI] [PMID] [Google Scholar]
80. Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol. 2017;9(5):227-41. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).